echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > J Allergy Clin Immunol: Efficacy and safety of omalizumab in the treatment of nasal polyposis: 2 randomized phase 3 trials

    J Allergy Clin Immunol: Efficacy and safety of omalizumab in the treatment of nasal polyposis: 2 randomized phase 3 trials

    • Last Update: 2021-08-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Chronic rhinitis with nasal polyps (CRSwNP) is characterized by excessive IgE secretion and eosinophil inflammation


    Adult patients with CRSwNP and insufficient response to intranasal corticosteroids were randomly (1:1) assigned to omalizumab or placebo and oral mometasone for 24 weeks


     

    The results showed that patients with POLYP 1 (n = 138) and POLYP 2 (n = 127) showed severe CRSwNP and significant quality of life impairment, with an average NPS higher than 6, and a SNOT-22 score of about 60


    In summary, omalizumab significantly improved the endoscopic, clinical and patient-reported results of severe CRSwNP with insufficient response to intranasal corticosteroids, and it was well tolerated


     

    Original source:

     

    Philippe Gevaert, Theodore A Omachi, et al.


    Efficacy and safety of omalizumab in nasal polyposis : 2 randomized phase 3 trials

    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.